Format

Send to

Choose Destination
Biol Neonate. 1994;66(6):311-5.

Myoclonus associated with lorazepam therapy in very-low-birth-weight infants.

Author information

1
Department of Paediatrics, St. Joseph's Health Centre, Lawson Research Institute, University of Western Ontario, London, Canada.

Abstract

Lorazepam is being used with increasing frequency as a sedative in the newborn and the young infant. Concern has been raised with regard to the safety of lorazepam in this age group, especially in very-low-birth-weight (VLBW; < 1,500 g) infants. Three young infants, all of birth weight < 1,500 g, experienced myoclonus following the intravenous administration of lorazepam. The potential neurotoxic effects of the drug (and its vehicle) in this population are discussed. Injectable lorazepam should be used with caution in VLBW infants.

PMID:
7727612
DOI:
10.1159/000244123
[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center